Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott McCallister

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
AIDS Research and Human Retroviruses|January 26, 2018
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of TreatmentEdwin DeJesus, Bernard Haas, Sorana Segal-Maurer, et al.
Open Forum Infectious Diseases|January 18, 2020
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil FumarateGregory D Huhn, David J Shamblaw, Jean-Guy Baril, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2007
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 studyMartin Markowitz, Leonard N Slater, Robert Schwartz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 26, 2020
Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016Dawn K Smith, Patrick S Sullivan, Betsy Cadwell, et al.
Annals of Epidemiology|July 10, 2018
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United StatesAaron J Siegler, Farah Mouhanna, Robertino Mera Giler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Annals of Epidemiology|February 24, 2020
Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictionsPatrick S Sullivan, Farah Mouhanna, Robertino Mera, et al.
Annals of Epidemiology|July 25, 2018
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017Patrick S Sullivan, Robertino Mera Giler, Farah Mouhanna, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
AIDS Research and Human Retroviruses|January 26, 2018
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of TreatmentEdwin DeJesus, Bernard Haas, Sorana Segal-Maurer, et al.
Open Forum Infectious Diseases|January 18, 2020
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil FumarateGregory D Huhn, David J Shamblaw, Jean-Guy Baril, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 8, 2007
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 studyMartin Markowitz, Leonard N Slater, Robert Schwartz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 26, 2020
Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016Dawn K Smith, Patrick S Sullivan, Betsy Cadwell, et al.
Annals of Epidemiology|July 10, 2018
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United StatesAaron J Siegler, Farah Mouhanna, Robertino Mera Giler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Annals of Epidemiology|February 24, 2020
Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictionsPatrick S Sullivan, Farah Mouhanna, Robertino Mera, et al.
Annals of Epidemiology|July 25, 2018
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017Patrick S Sullivan, Robertino Mera Giler, Farah Mouhanna, et al.
Pageof 4